Neurocrine Biosciences
Yahoo Finance • yesterday
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative?
Nxera Pharma recently announced that its partner Neurocrine Biosciences received FDA IND acceptance for a Phase 2 trial of NBI-1117567, an investigational oral muscarinic M1-preferring agonist for Alzheimer's cognition, triggering a US$10,... Full story
Yahoo Finance • 3 days ago
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Both Neurocrine Biosciences NBIX and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on specialty medicines and treatments for serious health conditions. NBIX focuses on neuroscience, with growth primarily led by... Full story
Yahoo Finance • 21 days ago
Neurocrine Biosciences Commences Phase 1 First-in-human Clinical Study Of NBIP-'1968
(RTTNews) - Friday, Neurocrine Biosciences, Inc. (NBIX) announced the commencement of a Phase 1 first-in-human clinical study, evaluating the safety and tolerability of NBIP-'1968 for the treatment of obesity. NBIP-'1968 is an investigati... Full story
Yahoo Finance • 28 days ago
Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Neurocrine Biosciences (NBIX) stock is in focus after the company reported second quarter 2026 r... Full story
Yahoo Finance • last month
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growt... Full story
Yahoo Finance • last month
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Neurocrine Biosciences (NasdaqGS:NBIX) has appointed Samir Siddhanti as Chief Business Officer. Siddhanti will also join th... Full story
Yahoo Finance • last month
Oppenheimer Picks Apple, Amazon, Alphabet as Top Stock Buys
This article first appeared on GuruFocus. Oppenheimer said investors may want to use the recent pullback in higher-beta stocks to selectively add equity exposure rather than adopt a defensive stance. The firm said recent market action re... Full story
Yahoo Finance • last month
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball
For Immediate Release Chicago, IL – July 16, 2026 – Stocks in this week's article are NVIDIA Corp. NVDA, Neurocrine Biosciences, Inc. NBIX and Ball Corp. BALL. NVIDIA & 2 Best Earnings Growth Stocks to Buy for 2H 2026 Earnings growth is... Full story
Yahoo Finance • 2 months ago
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference cal... Full story
Yahoo Finance • 2 months ago
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the high growth NASDAQ stocks to buy now. On June 15, Neurocrine Biosciences presented two-year Phase 3 data at ENDO 2026 showing that CRENESSITY (crinecerfont) improves growth outcomes i... Full story
Yahoo Finance • 2 months ago
Best Value Stocks to Buy for June 24th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 24: Navigator Holdings Ltd. NVGS: This global operator of a fleet of liquefied gas carriers carries a Zacks Rank #1, and has witnes... Full story
Yahoo Finance • 2 months ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story
Yahoo Finance • 2 months ago
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
Is NBIX a good stock to buy? We came across a bullish thesis on Neurocrine Biosciences, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on NBIX. Neurocrine Biosciences, Inc.'s share was trading at $159.7... Full story
Yahoo Finance • 3 months ago
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the 15 Most Promising Stocks to Buy Right Now. On May 29, 2026, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $183 from $180 and maintaine... Full story
Yahoo Finance • 3 months ago
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:(PRNewsfoto/Neurocrine Biosciences, Inc.) William Blair 46th An... Full story
Yahoo Finance • 3 months ago
A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why INGREZZA data matters for Neurocrine Biosciences stock Neurocrine Biosciences (NBIX) has drawn fresh attention af... Full story
Yahoo Finance • 3 months ago
Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced the presentation of new data from a clinician survey highlighting the functional impact of INGREZZA capsules on patients with mild tardive dyskinesia (TD) at American Psychiatric As... Full story
Yahoo Finance • 4 months ago
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide choline) for the Treatment of Hyperphagia i... Full story
Yahoo Finance • 4 months ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Acke... Full story
Yahoo Finance • 4 months ago
Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the first presentation of new two-year data from the Phase 3 CAHtalys... Full story